Fungal infections:

Indications for: NEBUPENT

For prevention of Pneumocystis jiroveci pneumonia (PJP) in high-risk, HIV-infected patients defined by one or both of the following criteria: 1) a history of one or more episodes of PJP; 2) a peripheral CD4+ lymphocyte count ≤200/mm3.

Adult Dosage:

>16yrs: 300mg once every 4 weeks administered via the Respirgard II nebulizer. Dose should be delivered until nebulizer chamber is empty (approx. 30–45 minutes).

Children Dosage:

≤16yrs: not recommended.

NEBUPENT Warnings/Precautions:

Exclude the presence of PJP before starting prophylaxis therapy. History of smoking or asthma. May induce bronchospasm/cough; administer inhaled bronchodilator prior to giving NebuPent dose; do not use Respirgard II nebulizer to administer a bronchodilator. Pregnancy (Cat. C). Nursing mothers: not recommended.

NEBUPENT Classification:


NEBUPENT Interactions:

Do not mix with other drugs. Additive effects with concomitant other nephrotoxic drugs (eg, aminoglycosides, amphotericin B, cisplatin, foscarnet, vancomycin); monitor closely or avoid if possible.

Adverse Reactions:

Night sweats, GI upset, anemia, bronchitis, herpes, herpes zoster, flu, oral Candida, pharyngitis, sinusitis, upper respiratory tract infections, headache, chest pain, cough, wheezing, bad taste; monitor closely for serious adverse reactions: hypotension, hypoglycemia, hyperglycemia, hypocalcemia, thrombocytopenia, leukopenia, hepatic/renal dysfunction, ventricular tachycardia, pancreatitis (discontinue if occurs), Stevens-Johnson syndrome, hyperkalemia, abnormal ST segment; rare: extrapulmonary pneumocystosis.

How Supplied:

Single-dose vial—1